Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


GREY:CLAZF - Post by User

Comment by PTBaileyon Sep 17, 2021 9:37am
86 Views
Post# 33876681

RE:RE:RE:RE:Analysis on todays NR

RE:RE:RE:RE:Analysis on todays NR
Dude51 wrote: Sure thing Yukon err.

Since its inception in July 2014, Claritas has accumulated a deficit of approximately $59.2 million as at June 30, 2021. The Company did not generate any revenue from product sales during the three months period ended June 30, 2021. Claritas expects its operating losses to continue in the next fiscal year as it invests in its product development programs.

Go here https://claritasinvestors.com/, check out Investors trueisms. Spanked Drew

GO THRM GO, FDA, anyday. Watch Rob ceo thrm videos, search youtubel


Since claritas is a R&D company using money rasied by investors and private placements they are are working towards producing something that other pharma companies will aquire licenses and put to market. 

A $59.2 million defecit does not mean they have debt, actually I beleive they are debt free. And I would say you are correct they will invest more money in completing phase 1 and 2.

So do we consider that losing money and is the alternative to quit or keep investing to complete these phases?
<< Previous
Bullboard Posts
Next >>